NextCure, Inc. Common Stock
Symbol: NXTC (NASDAQ)
Company Description:
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $11.79
- Yesterday High: $12.25
- Yesterday Low: $10.51
- Yesterday Volume: 86.91K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: NextCure, Inc. Common Stock
- Website: https://www.nextcure.com
- Listed Date: 2019-05-09
- Location: BELTSVILLE, MD
- Market Status: Active
- CIK Number: 0001661059
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $28.96M
- Round Lot: 100
- Outstanding Shares: 2.68M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-29 | 3/A | View |
| 2025-08-25 | 8-K | View |
| 2025-08-19 | SCHEDULE 13G | View |
| 2025-08-19 | 3 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-29 | EFFECT | View |
| 2025-07-29 | 424B2 | View |
| 2025-07-28 | CORRESP | View |
| 2025-07-24 | UPLOAD | View |
| 2025-07-18 | S-3 | View |
| 2025-07-14 | 8-K | View |
| 2025-07-10 | 8-K | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-24 | 4 | View |
| 2025-06-23 | 8-K | View |